Can Psychedelics Restore Consciousness? The Trial Design Problem Nobody Is Ready For
A Molecular Psychiatry review asks whether psilocybin can reach minimally conscious patients, and exposes the outcome measurement gaps trials...
GLP-1 Drugs Linked to Fewer Psychiatric Hospitalizations in People With Schizophrenia and Type 2 Diabetes
A Lancet Psychiatry cohort of 70,257 schizophrenia patients shows GLP-1 agonists reduce acute psychiatric care. Trial design hasn't caught...
The Psilocybin Layer 5 Finding Changes How I Think About What We’re Actually Dosing For
A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape how we design...
Psilocybin Moves the Social Brain in AUD, And Our Trial Endpoints Are Missing It
A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind...
Amygdala Ultrasound in Depression: What the First Human Data Reveals About Neuromodulation’s Next Frontier
First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, endpoint design, and...
What the Lancet Psychiatry Mania Data Gets Right, and What It Still Can’t Tell Us
A new target trial emulation in Lancet Psychiatry challenges antipsychotic-first strategies in early psychotic mania. Here's what it means...
What the FDA’s New Psychedelic Framework Actually Means for the Clinic
FDA's September 2026 NEJM framework for psychedelic drugs reshapes trial design, REMS requirements, and patient access for psilocybin and...
The Mitochondrial Switch That Makes Drugs Different From Food
New Nature Neuroscience data shows MCU inhibition blocks drug reward without touching natural reward circuits, a mechanistic breakthrough for...
Dronabinol for PTSD Nightmares Is Promising, and the Dual Diagnosis Question Changes Everything
A Nature Medicine RCT shows dronabinol cuts PTSD nightmares. For the 46% of PTSD patients who also carry a...
LSD Just Beat Phase 3 Twice. Now Comes the Hard Part.
Definium's DT120 cleared Phase 3 in both MDD and GAD. As a ketamine PI who's treated 30,000+ patients, here's...